Oyster Point Pharma CEO Jeffrey Nau Highlights Details of the Company’s Recent B Round, Ponders IPO

OIS Podcast | Ophthalmology's leading Podcast

English - April 10, 2019 04:00 - 31 minutes - 14.6 MB - ★★★★★ - 30 ratings
Investing Business Health & Fitness ophthalmology investment venture capital entrepreneurs oftalmólogo ophthalmic key opinion leader seco ascrs aao Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Novaliq’s Bernhard Günther Reveals Company’s Fateful Start, Promising Future for Dry Eye Treatments

Next Episode: Oculis CEO Riad Sherif Talks About Novartis, Alcon, and What’s Promising in His Company’s Pipeline

With more than $100 million raised in venture capital and three late-stage clinical programs, Oyster Point Pharma is getting a lot done in a short amount of time. In this podcast, CEO and president Jeffrey Nau reveals how the company is working so quickly and ponders what the next major milestone might be.